Series C · Biotech

Isomorphic Labs raises $5bn Series C for AI drug discovery

Greenoaks and Sequoia Capital co-led the round as the company develops its drug-design engine and therapeutic pipeline.

Isomorphic Labs announced a $5 billion Series C on November 17, co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI fund also participated.

The company uses AI to design drug candidates across therapeutic areas. The financing will support research on its drug-design engine and the development of its therapeutic pipeline, linking advances in molecular prediction with compounds intended for clinical development.

Use of funds

Drug design engine and AI research

Therapeutic candidate pipeline

Funding history

Series C · This round$5B
Series B$2.1B

Sources

  1. Isomorphic Labs Series C financing announcementisomorphiclabs.com · Nov 17, 2026
  2. Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic Labstech.eu · Nov 17, 2026